Cargando…

Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate

Background: Malignant neoplasms of the salivary glands are rare, and therapeutic options are limited. Results from recently published studies indicate a possible use for checkpoint inhibition in a subset of patients, but there are no established criteria for programme cell death ligand 1 (PD-L1) sco...

Descripción completa

Detalles Bibliográficos
Autores principales: Witte, Hanno M., Gebauer, Niklas, Lappöhn, Daniela, Umathum, Vincent G., Riecke, Armin, Arndt, Annette, Steinestel, Konrad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226358/
https://www.ncbi.nlm.nih.gov/pubmed/32260165
http://dx.doi.org/10.3390/cancers12040873
_version_ 1783534268567257088
author Witte, Hanno M.
Gebauer, Niklas
Lappöhn, Daniela
Umathum, Vincent G.
Riecke, Armin
Arndt, Annette
Steinestel, Konrad
author_facet Witte, Hanno M.
Gebauer, Niklas
Lappöhn, Daniela
Umathum, Vincent G.
Riecke, Armin
Arndt, Annette
Steinestel, Konrad
author_sort Witte, Hanno M.
collection PubMed
description Background: Malignant neoplasms of the salivary glands are rare, and therapeutic options are limited. Results from recently published studies indicate a possible use for checkpoint inhibition in a subset of patients, but there are no established criteria for programme cell death ligand 1 (PD-L1) scoring in salivary gland carcinomas (SGCs). Methods: In this retrospective study, we present a cohort of 94 SGC patients with full clinical follow-up. We included 41 adenoid cystic carcinomas (AdCC), 21 mucoepidermoid carcinomas (MEC), 16 acinic cell carcinomas (ACC), 12 adenocarcinomas, not otherwise specified (AC, NOS), 2 epithelial-myoepithelial carcinomas (EMC), one salivary duct carcinoma (SDC), and one carcinoma ex pleomorphic adenoma (CA ex PA). Subsequent histopathological analysis was performed with special emphasis on the composition of the immune cell infiltrate (B-/T-lymphocytes). We assessed PD-L1 (SP263) on full slides by established scoring criteria: tumor proportion score (TPS), combined positivity score (CPS) and immune cell (IC) score. Results: We identified significantly elevated CD3+, TP, CP, and IC scores in AC, NOS compared to AdCC, MEC, and ACC. CPS correlated with node-positive disease. Moreover, AC, NOS displayed IC scores of 2 or 3 in the majority (67%) of cases (p = 0.0031), and was associated with poor prognosis regarding progression-free (PFS) (p < 0.0001) and overall survival (OS) (p < 0.0001). CPS correlated with strong nuclear or null p53 staining in AC, NOS but not in other SGCs. Long-lasting partial remission could be achieved in one AC, NOS patient who received Pembrolizumab as third-line therapy. Conclusions: The current study is the first to investigate the use of established scoring criteria for PD-L1 expression in malignant salivary gland tumors. Our findings identify unique characteristics for AC, NOS among the family of SGCs, as it is associated with poor prognosis and might represent a valuable target for immune checkpoint inhibition.
format Online
Article
Text
id pubmed-7226358
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72263582020-05-18 Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate Witte, Hanno M. Gebauer, Niklas Lappöhn, Daniela Umathum, Vincent G. Riecke, Armin Arndt, Annette Steinestel, Konrad Cancers (Basel) Article Background: Malignant neoplasms of the salivary glands are rare, and therapeutic options are limited. Results from recently published studies indicate a possible use for checkpoint inhibition in a subset of patients, but there are no established criteria for programme cell death ligand 1 (PD-L1) scoring in salivary gland carcinomas (SGCs). Methods: In this retrospective study, we present a cohort of 94 SGC patients with full clinical follow-up. We included 41 adenoid cystic carcinomas (AdCC), 21 mucoepidermoid carcinomas (MEC), 16 acinic cell carcinomas (ACC), 12 adenocarcinomas, not otherwise specified (AC, NOS), 2 epithelial-myoepithelial carcinomas (EMC), one salivary duct carcinoma (SDC), and one carcinoma ex pleomorphic adenoma (CA ex PA). Subsequent histopathological analysis was performed with special emphasis on the composition of the immune cell infiltrate (B-/T-lymphocytes). We assessed PD-L1 (SP263) on full slides by established scoring criteria: tumor proportion score (TPS), combined positivity score (CPS) and immune cell (IC) score. Results: We identified significantly elevated CD3+, TP, CP, and IC scores in AC, NOS compared to AdCC, MEC, and ACC. CPS correlated with node-positive disease. Moreover, AC, NOS displayed IC scores of 2 or 3 in the majority (67%) of cases (p = 0.0031), and was associated with poor prognosis regarding progression-free (PFS) (p < 0.0001) and overall survival (OS) (p < 0.0001). CPS correlated with strong nuclear or null p53 staining in AC, NOS but not in other SGCs. Long-lasting partial remission could be achieved in one AC, NOS patient who received Pembrolizumab as third-line therapy. Conclusions: The current study is the first to investigate the use of established scoring criteria for PD-L1 expression in malignant salivary gland tumors. Our findings identify unique characteristics for AC, NOS among the family of SGCs, as it is associated with poor prognosis and might represent a valuable target for immune checkpoint inhibition. MDPI 2020-04-03 /pmc/articles/PMC7226358/ /pubmed/32260165 http://dx.doi.org/10.3390/cancers12040873 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Witte, Hanno M.
Gebauer, Niklas
Lappöhn, Daniela
Umathum, Vincent G.
Riecke, Armin
Arndt, Annette
Steinestel, Konrad
Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate
title Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate
title_full Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate
title_fullStr Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate
title_full_unstemmed Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate
title_short Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate
title_sort prognostic impact of pd-l1 expression in malignant salivary gland tumors as assessed by established scoring criteria: tumor proportion score (tps), combined positivity score (cps), and immune cell (ic) infiltrate
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226358/
https://www.ncbi.nlm.nih.gov/pubmed/32260165
http://dx.doi.org/10.3390/cancers12040873
work_keys_str_mv AT wittehannom prognosticimpactofpdl1expressioninmalignantsalivaryglandtumorsasassessedbyestablishedscoringcriteriatumorproportionscoretpscombinedpositivityscorecpsandimmunecellicinfiltrate
AT gebauerniklas prognosticimpactofpdl1expressioninmalignantsalivaryglandtumorsasassessedbyestablishedscoringcriteriatumorproportionscoretpscombinedpositivityscorecpsandimmunecellicinfiltrate
AT lappohndaniela prognosticimpactofpdl1expressioninmalignantsalivaryglandtumorsasassessedbyestablishedscoringcriteriatumorproportionscoretpscombinedpositivityscorecpsandimmunecellicinfiltrate
AT umathumvincentg prognosticimpactofpdl1expressioninmalignantsalivaryglandtumorsasassessedbyestablishedscoringcriteriatumorproportionscoretpscombinedpositivityscorecpsandimmunecellicinfiltrate
AT rieckearmin prognosticimpactofpdl1expressioninmalignantsalivaryglandtumorsasassessedbyestablishedscoringcriteriatumorproportionscoretpscombinedpositivityscorecpsandimmunecellicinfiltrate
AT arndtannette prognosticimpactofpdl1expressioninmalignantsalivaryglandtumorsasassessedbyestablishedscoringcriteriatumorproportionscoretpscombinedpositivityscorecpsandimmunecellicinfiltrate
AT steinestelkonrad prognosticimpactofpdl1expressioninmalignantsalivaryglandtumorsasassessedbyestablishedscoringcriteriatumorproportionscoretpscombinedpositivityscorecpsandimmunecellicinfiltrate